Bruen, Charles
Al-Saadi, Mukhtar
Michelson, Edward A.
Tanios, Maged
Mendoza-Ayala, Raul
Miller, Joseph
Zhang, Jeffrey
Stauderman, Kenneth
Hebbar, Sudarshan
Hou, Peter C.
Funding for this research was provided by:
CalciMedica, Inc, La Jolla, CA
Article History
Received: 7 January 2022
Accepted: 23 March 2022
First Online: 8 April 2022
Declarations
:
: The trial protocol was approved by an institutional review board at each site and was overseen by an IDMC. The trial was conducted in accordance with Good Clinical Practice guidelines and guiding principles of the Declaration of Helsinki and was approved by the local institutional review boards. Informed consent was obtained from either the patient or from the patient’s legally authorized representative if the patient was unable to provide consent. This trial is registered at ClinicalTrials.gov number, NCT04345614.
: Not applicable.
: KS and SH are full time employees of CalciMedica and hold stock options. CB and RMA report consulting fees not related to this manuscript with CalciMedica. JM reports grants to institution from CalciMedica. PCH reports grant/contract payments made to his institution from CalciMedica, National Institute of Health, US Department of Defense, US Center for Disease Control, Good Ventures, Rapid Pathogen Screening, Novartis, Kinevant Sciences GmbH, Mesoblast, Ophirex, Inc., Faron Pharmaceuticals, Day Zero Diagnostics, and iDoc Telehealth Solutions. JZ reports payment and consultant fees to Princeton Pharmatech. MA, MT, and EM report no conflicts of interest.